Consult the medical resource doctors trust

UpToDate is one of the most respected medical information resources in the world, used by over 360,000 doctors and thousands of patients to find answers to medical questions.

  • Content written by a faculty of over 4,000 physicians from leading medical institutions
  • Unbiased: free of advertising or pharmaceutical funding
  • Evidence-based treatment recommendations
  • Continuously updated to incorporate new medical findings

Epidemiology; pathogenesis; and classification of cholangiocarcinoma

INTRODUCTION

Cholangiocarcinomas (bile duct cancers) arise from the epithelial cells of the intrahepatic and extrahepatic bile ducts. Although these cancers are rare in the United States, they are highly lethal because most are locally advanced at presentation.

The epidemiology, pathology, pathogenesis, and classification of cholangiocarcinoma will be discussed here. Clinical manifestations, diagnosis, and treatment are reviewed separately. (See "Clinical manifestations and diagnosis of cholangiocarcinoma" and "Treatment of cholangiocarcinoma".)

Cancers of the gall bladder and ampulla of Vater are discussed as separate disease processes, although these structures are part of the biliary drainage system. (See "Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis" and "Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging".)

ANATOMY, TUMOR CLASSIFICATION AND STAGING

Biliary tract cancers were traditionally divided into cancers of the gallbladder, the extrahepatic ducts, and the ampulla of Vater, while intrahepatic tumors were classified as primary liver cancers. More recently, the term cholangiocarcinoma has been used to refer to bile duct cancers arising in the intrahepatic, perihilar, or distal (extrahepatic) biliary tree, exclusive of the gallbladder or ampulla of Vater (figure 1). Intrahepatic cholangiocarcinomas originate from small intrahepatic ductules (termed peripheral cholangiocarcinomas) or large intrahepatic ducts proximal to the bifurcation of the right and left hepatic ducts. The extrahepatic bile ducts are divided into perihilar (including the confluence itself) and distal segments, with the transition occurring at the point where the common bile duct lies posterior to the duodenum [1].

Bismuth-Corlette classification — Cancers arising in the perihilar region have been further classified according to their patterns of involvement of the hepatic ducts (the Bismuth-Corlette classification) (figure 2) [2]:

To continue reading this article you need to subscribe.

Read the rest of this article and others like it

The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use (click here) ©2009 UpToDate, Inc.
References Top
  1. de Groen, PC, Gores, GJ, LaRusso, NF, et al. Biliary tract cancers. N Engl J Med 1999; 341:1368.
  2. Bismuth, H, Nakache, R, Diamond, T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg 1992; 215:31.
  3. AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 6th ed, Greene, FL, Page, DL, Fleming, ID, et al (Eds), Springer-Verlag, New York 2002.
  4. Nathan, H, Aloia, TA, Vauthey, JN, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 2009; 16:14.
  5. Zervos, EE, Osborne, D, Goldin, SB, et al. Stage does not predict survival after resection of hilar cholangiocarcinomas promoting an aggressive operative approach. Am J Surg 2005; 190:810.
  6. Hong, SM, Pawlik, TM, Cho, H, et al. Depth of tumor invasion better predicts prognosis than the current American Joint Committee on Cancer T classification for distal bile duct carcinoma. Surgery 2009; 146:250.
  7. Vauthey, JN, Blumgart, LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 1994; 14:109.
  8. Jemal, A, Siegel, R, Ward, E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106.
  9. Patel, T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33:1353.
  10. Shaib, YH, Davila, JA, McGlynn, K, El-Serag, HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?. J Hepatol 2004; 40:472.
  11. Jepsen, P, Vilstrup, H, Tarone, RE, et al. Incidence rates of intra- and extrahepatic cholangiocarcinomas in Denmark from 1978 through 2002. J Natl Cancer Inst 2007; 99:895.
  12. West, J, Wood, H, Logan, RF, et al. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer 2006; 94:1751.
  13. Rajagopalan, V, Daines, WP, Grossbard, ML, Kozuch, P. Gallbladder and biliary tract carcinoma: A comprehensive update, Part 1. Oncology (Huntingt) 2004; 18:889.
  14. Khan, SA, Taylor-Robinson, SD, Toledano, MB, et al. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002; 37:806.
  15. Patel, T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2:10.
  16. Welzel, TM, McGlynn, KA, Hsing, AW, et al. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2006; 98:873.
  17. Jarnagin, WR. Cholangiocarcinoma of the extrahepatic bile ducts. Semin Surg Oncol 2000; 19:156.
  18. Shaib, YH, El-Serag, HB, Davila, JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: A case-control study. Gastroenterology 2005; 128:620.
  19. Broome, U, Olsson, R, Loof, L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38:610.
  20. Henson, DE, Albores-Saavedra, J, Corle, D. Carcinoma of the extrahepatic bile ducts. Histologic types, stage of disease, grade, and survival rates. Cancer 1992; 70:1498.
  21. Berthiaume, EP, Wands, J. The molecular pathogenesis of cholangiocarcinoma. Semin Liver Dis 2004; 24:127.
  22. Ohashi, K, Nakajima, Y, Kanehiro, H, et al. Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: Relation to gross tumor pathology. Gastroenterology 1995; 109:1612.
  23. Aishima, SI, Taguchi, KI, Sugimachi, K, et al. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology 2002; 40:269.
  24. Terada, T, Nakanuma, Y, Sirica, AE. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol 1998; 29:175.
  25. Isa, T, Tomita, S, Nakachi, A, et al. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 2002; 49:604.
  26. Diamantis, I, Karamitopoulou, E, Perentes, E, et al. P53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer. Hepatology 1995; 22:774.
  27. Rizzi, PM, Ryder, SD, Portmann, PB, et al. P53 overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis. Gut 1996; 38:265.
  28. Suto, T, Sugai, T, Nakamura, S, et al. Assessment of the expression of p53, MIB-1 (Ki-67 antigen), and argyrophilic nucleolar organizer regions in carcinoma of the extrahepatic bile duct. Cancer 1998; 82:86.
  29. Ahrendt, SA, Rashid, A, Chow, JT, et al. p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. J Hepatobiliary Pancreat Surg 2000; 7:426.
  30. Tannapfel, A, Weinans, L, Geissler, F, et al. Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver. Dig Dis Sci 2000; 45:317.
  31. Nehls, O, Gregor, M, Klump, B. Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 2004; 24:139.
  32. Wang, Y, Yamaguchi, Y, Watanabe, H, et al. Usefulness of p53 gene mutations in the supernatant of bile for diagnosis of biliary tract carcinoma: comparison with K- ras mutation. J Gastroenterol 2002; 37:831.
  33. Taniai, M, Higuchi, H, Burgart, LJ, Gores, GJ. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 2002; 123:1090.
  34. Tannapfel, A, Benicke, M, Katalinic, A, et al. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 2000; 47:721.
  35. Momoi, H, Okabe, H, Kamikawa, T, et al. Comprehensive allelotyping of human intrahepatic cholangiocarcinoma. Clin Cancer Res 2001; 7:2648.
  36. Que, FG, Phan, VA, Phan, VH, et al. Cholangiocarcinomas express Fas ligand and disable the Fas receptor. Hepatology 1999; 30:1398.
  37. Chapman, RW. Risk factors for biliary tract carcinogenesis. Ann Oncol 1999; 10 Suppl 4:308.
  38. Tung, BY, Brentnall, T, Kowdley, KV, et al. Diagnosis and prevalence of ulcerative colitis in patients with primary sclerosing cholangitis (abstract). Hepatology 1996; 24:169A.
  39. Bergquist, A, Ekbom, A, Olsson, R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36:321.
  40. Lee, YM, Kaplan, MM. Primary sclerosing cholangitis. N Engl J Med 1995; 332:924.
  41. Wiesner, RH. Current concepts in primary sclerosing cholangitis. Mayo Clin Proc 1994; 69:969.
  42. Bergquist, A, Glaumann, H, Persson, B, Broome, U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: A case-control study. Hepatology 1998; 27:311.
  43. de Groen, PC. Cholangiocarcinoma in primary sclerosing cholangitis: who is at risk and how do we screen? [editorial; comment]. Hepatology 2000; 31:247.
  44. Burak, K, Angulo, P, Pasha, TM, et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004; 99:523.
  45. Claessen, MM, Vleggaar, FP, Tytgat, KM, et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009; 50:158.
  46. Rosen, CB, Nagorney, DM, Wiesner, RH, et al. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991; 213:21.
  47. LaRusso, NF, Wiesner, RH, Ludwig, J, MacCarty, RL. Current concepts. Primary sclerosing cholangitis. N Engl J Med 1984; 310:899.
  48. Chalasani, N, Baluyut, A, Ismail, A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study. Hepatology 2000; 31:7.
  49. Melum, E, Karlsen, TH, Schrumpf, E, et al. Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology 2008; 47:90.
  50. Hultcrantz, R, Olsson, R, Danielsson, A, et al. A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 1999; 30:669.
  51. Levy, C, Lymp, J, Angulo, P, et al. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 2005; 50:1734.
  52. Rea, DJ, Heimbach, JK, Rosen, CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 242:451.
  53. Khan, SA, Thomas, HC, Davidson, BR, Taylor-Robinson, SD. Cholangiocarcinoma. Lancet 2005; 366:1303.
  54. Scott, J, Shousha, S, Thomas, HC, Sherlock, S. Bile duct carcinoma: a late complication of congenital hepatic fibrosis. Case report and review of literature. Am J Gastroenterol 1980; 73:113.
  55. Lipsett, PA, Pitt, HA, Colombani, PM, et al. Choledochal cyst. A changing pattern of presentation. Ann Surg 1994; 220:644.
  56. Dayton, MT, Longmire, WP, Tompkins, RK. Caroli's disease: A premalignant condition? Am J Surg 1983; 145:41.
  57. Watanapa, P. Cholangiocarcinoma in patients with opisthorchiasis. Br j Surg 1996; 83:1062.
  58. Watanapa, P, Watanapa, WB. Liver fluke-associated cholangiocarcinoma. Br J Surg 2002; 89:962.
  59. Shin, HR, Lee, CU, Park, HJ, et al. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol 1996; 25:933.
  60. Honjo, S, Srivatanakul, P, Sriplung, H, et al. Genetic and environmental determinants of risk for cholangiocarcinoma via Opisthorchis viverrini in a densely infested area in Nakhon Phanom, northeast Thailand. Int J Cancer 2005; 117:854.
  61. Hsing, AW, Gao, YT, Han, TQ, et al. Gallstones and the risk of biliary tract cancer: a population-based study in China. Br J Cancer 2007; 97:1577.
  62. Ahrens, W, Timmer, A, Vyberg, M, et al. Risk factors for extrahepatic biliary tract carcinoma in men: medical conditions and lifestyle: results from a European multicentre case-control study. Eur J Gastroenterol Hepatol 2007; 19:623.
  63. Welzel, TM, Mellemkjaer, L, Gloria, G, et al. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer 2007; 120:638.
  64. Chijiiwa, K, Yamashita, H, Yoshida, J, et al. Current management and long-term prognosis of hepatolithiasis. Arch Surg 1995; 130:194.
  65. Lee, CC, Wu, CY, Chen, GH. What is the impact of coexistence of hepatolithiasis on cholangiocarcinoma?. J Gastroenterol Hepatol 2002; 17:1015.
  66. Chen, MF. Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment. J Gastroenterol Hepatol 1999; 14:1144.
  67. Su, CH, Shyr, YM, Lui, WY, P'Eng, FK. Hepatolithiasis associated with cholangiocarcinoma. Br J Surg 1997; 84:969.
  68. Kinami, Y, Noto, H, Miyazaki, I, et al. A study of hepatolithiasis associated with cholangiocarcinoma. Acta Hepatol Jpn 1978; 19:573.
  69. Yamamoto, K, Tsuchiya, R, Ito, I, et al. A study of cholangiocarcinoma coexisting with hepatolithiasis. Jpn J Gastroenterol Surg 1984; 17:601.
  70. Okuda, K, Kubo, Y, Okazaki, N, et al. Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma: a study of 57 autopsy-proven cases. Cancer 1977; 39:232.
  71. Donato, F, Gelatti, U, Tagger, A, et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control 2001; 12:959.
  72. Kim, YT, Byun, JS, Kim, J, et al. Factors predicting concurrent cholangiocarcinomas associated with hepatolithiasis. Hepatogastroenterology 2003; 50:8.
  73. Sahani, D, Prasad, SR, Tannabe, KK, et al. Thorotrast-induced cholangiocarcinoma: case report. Abdom Imaging 2003; 28:72.
  74. Welzel, TM, Graubard, BI, El-Serag, HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007; 5:1221.
  75. Zhou, YM, Yin, ZF, Yang, JM, et al. Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol 2008; 14:632.
  76. Shaib, YH, El-Serag, HB, Nooka, AK, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol 2007; 102:1016.
  77. Grainge, MJ, West, J, Solaymani-Dodaran, M, et al. The antecedents of biliary cancer: a primary care case-control study in the United Kingdom. Br J Cancer 2009; 100:178.
  78. Mecklin, JP, Jarvinen, HJ, Virolainen, M. The association between cholangiocarcinoma and hereditary nonpolyposis colorectal carcinoma. Cancer 1992; 69:1112.
  79. Lee, SS, Kim, MH, Lee, SK, et al. Clinicopathologic review of 58 patients with biliary papillomatosis. Cancer 2004; 100:783.
  80. Taguchi, J, Yasunaga, M, Kojiro, M, et al. Intrahepatic and extrahepatic biliary papillomatosis. Arch Pathol Lab Med 1993; 117:944.
  81. Kobayashi, M, Ikeda, K, Saitoh, S, et al. Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis C virus-related cirrhosis. Cancer 2000; 88:2471.
  82. Sorensen, HT, Friis, S, Olsen, JH, et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 1998; 28:921.
  83. Nagaoka, T, Ohkawa, S, Ito, Y, et al. [A case of minute cholangiocellular carcinoma which was found in the follow-up periods of liver cirrhosis and was indistinguishable from hepatocellular carcinoma on hepatic angiography]. Nippon Shokakibyo Gakkai Zasshi 1991; 88:1369.
  84. Hsing, AW, Zhang, M, Rashid, A, et al. Hepatitis B and C virus infection and the risk of biliary tract cancer: a population-based study in China. Int J Cancer 2008; 122:1849.
  85. Yamamoto, S, Kubo, S, Hai, S, et al. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci 2004; 95:592.
  86. Liu, XF, Zou, SQ, Qiu, FZ. Pathogenesis of cholangiocarcinoma in the porta hepatis and infection of hepatitis virus. Hepatobiliary Pancreat Dis Int 2003; 2:285.
  87. Okuda, K, Nakanuma, Y, Miyazaki, M. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol 2002; 17:1049.
  88. Lu, H, Ye, MQ, Thung, SN, et al. Detection of hepatitis C virus RNA sequences in cholangiocarcinomas in Chinese and American patients. Chin Med J (Engl) 2000; 113:1138.
  89. El-Serag, HB, Engels, EA, Landgren, O, et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology 2009; 49:116.
  90. Lee, CH, Chang, CJ, Lin, YJ, et al. Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma. Br J Cancer 2009; 100:1765.
  91. Wideroff, L, Gridley, G, Mellemkjaer, L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997; 89:1360.
  92. Adami, HO, Chow, WH, Nyren, O, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996; 88:1472.
  93. Nakeeb, A, Pitt, HA, Sohn, TA, et al. Cholangiocarcinoma: A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996; 224:463.
  94. Jarnagin, WR, Bowne, W, Klimstra, DS, et al. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg 2005; 241:703.
  95. Martin, RC, Klimstra, DS, Schwartz, L, et al. Hepatic intraductal oncocytic papillary carcinoma. Cancer 2002; 95:2180.
  96. Nakanuma, Y, Harada, K, Ishikawa, A, et al. Anatomic and molecular pathology of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2003; 10:265.
white circle LOG IN
white circle DEMO